TOCA is pleased to announce that David S Bailie MD has been selected as a principal investigator of a new stemless total shoulder replacement device.

TOCA is pleased to announce that David S Bailie MD has been selected as a principal investigator of a new stemless total shoulder replacement device. This is a randomized study being conducted at 12 FDA approved medical facilities in the US. Dr. Bailie is the only orthopedic surgeon approved to use this device in the western US (west of  Memphis, TN). 

This FDA approved study is being sponsored by Biomet Orthopedics ( a worldwide manufacturer/distributor of Orthopedic devices, www.Biomet.com). 

Dr. Bailie has been selected by the FDA and the Western Institutional Review Board to participate and enroll qualified patients. The device has already been released and is currently being used in several European countries and the UK. Because the device is uniquely different than any current shoulder replacement on the market, in the US it requires a specifically designed FDA approved study, to be conducted by select surgeons, prior to general release to the remainder of the medical community. Until the study is complete (approximately 5-7 years), it will only be available as part of this study. Dr. Bailie is very excited to have been asked to participate in this "cutting-edge" research and be able to offer his patients a unique opportunity to participate. Participating orthopedic surgeons is by invitation only.

As criteria for patients to be included in this study is very specific and narrow, only those potential patients who are seen and examined personally by Dr. Bailie can be considered. This study will be performed under strict FDA and IRB monitoring until it is completed.



TOCA
602-277-6211
www.tocamd.com